Paul is a Senior Vice President of Research at Vertex Pharmaceuticals, where he is currently Disease Area Executive for Vertex’s Pain Program. From 2003-2022 Paul was Site Head for Vertex’s San Diego Research Site which focused on developing treatments for Cystic fibrosis and pain. Paul and his team pioneered the development of CFTR modulators which restore the function of the defective CFTR protein, resulting in five marketed products (Kalydeco, Orkambi, Symdeko, Trikafta, Alyftrek). Trikafta and Alyftrek are triple drug combinations that could treat approximately 90% of people with CF. In pain, Paul and his team discovered and developed the first marketed selective NaV1.8 channel inhibitor (Journavx) as a novel, non-opioid option to treat moderate to severe acute pain.